These are top 10 stocks traded on the Robinhood UK platform in July
Creative Medical (TASE:BLWV) Technology Holdings Inc. (CELZ) stock has reached a 52-week low, dipping to $1.9, representing a stark 72% decline from its 52-week high of $6.90. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 18.7x and holds more cash than debt on its balance sheet. This latest price level reflects a significant downturn from the previous year, with the stock experiencing a 1-year change of -65.61%. Investors are closely monitoring CELZ as it hits this low point, considering the broader implications for the biotech sector and the company's strategic moves to recover value. InvestingPro's Fair Value analysis suggests the stock may be undervalued at current levels, with additional insights and 12 more ProTips available for subscribers.
In other recent news, Creative Medical Technology Holdings, Inc. has announced several significant developments. The company revealed that the FDA has approved an expanded dose escalation for its Phase 1/2 StemSpine® trial, which is investigating AlloStem™ for chronic lower back pain. Interim data from the trial has shown notable pain reduction and improved mobility among participants, with no serious adverse effects reported. Additionally, Creative Medical Technology has secured $3.7 million through the exercise of warrants, advised by Roth Capital Partners (WA:CPAP), to support working capital and general corporate purposes.
In another development, the company reported promising results from its AlloStem™ Type 2 Diabetes pilot study, showing an 80% efficacy rate in reducing insulin dependency. The study confirmed the safety and efficacy of CELZ-201, with plans for further development. Creative Medical Technology has also entered a strategic collaboration with Greenstone Biosciences Inc. to incorporate AI in advancing its stem cell platform for diabetes treatment. This partnership aims to enhance insulin secretion and optimize cell function through AI-driven drug discovery and multi-gene editing.
These advancements highlight Creative Medical Technology's commitment to regenerative medicine, with ongoing efforts to improve therapeutic outcomes and explore new applications for its technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.